PHASE 1/2A OPEN-LABEL CLINICAL TRIAL EVALUATING VBC101, AN EGFR AND CMET TARGETED BI-SPECIFIC ANTIBODY DRUG CONJUGATE, IN PARTICIPANTS WITH ADVANCED SOLID TUMOR MALIGNANCIES

Inclusion Criteria: * A participant must meet all of the following inclusion criteria to be eligible to participate in this trial: * 1\. The participant or the participant's legally acceptable representative is willing and able to provide a written ICF before initiating any trial procedure. * 2\. Histologically or cytologically confirmed unresectable advanced/metastatic solid tumor that has relapsed or progressed on or after standard systemic treatments, or is intolerable with standard treatment, or for which no standard treatment is available * 3\. At least one measurable lesion as assessed by the investigator according to RECIST v1.1criteria * 4\. Male or female adults (defined as ≥ 18 years of age) * 5\. ECOG performance status 0-1 * 6\. Has LVEF ≥ 50% by either ECHO or MUGA within 28 days before enrollment. * 7\. Life expectancy greater than 12 weeks * 8\. Archived tumor tissue sample available or able to undergo a fresh biopsy collection. * 9\. Adequate organ and bone marrow function * 10\. Participants must meet the minimum washout period requirements before the first dose of investigational drug Exclusion Criteria: 1\. Any unresolved toxicity of Grade ≥2 from previous anti-cancer treatment, except for alopecia, neuropathy, or skin pigmentation changes. Participants with chronic but stable Grade 2 toxicities may be allowed to enroll after agreement between the study investigator and the Sponsor's Medical Monitor. * 2\. Known or suspected brain metastases, or spinal cord compression, unless the condition has been treated, asymptomatic, and has been stable without requiring escalating doses of corticosteroids (equivalent to ≤10 mg/day prednisone) or anti-convulsant medications for at least four weeks prior for the first dose of investigational drug. * 3\. Prior treatment with an ADC targeting EGFR and/or cMet (including VBC101) * 4\. Prior treatment with any ADC carrying a TOP1i payload (including prior VBC101). * 5\. Has a medical history of interstitial lung diseases (e.g., non-infectious interstitial pneumonia, pneumonitis, pulmonary fibrosis, and severe radiation pneumonitis) or current interstitial lung diseases or who are suspected to have these diseases by imaging at screening.